Status:
COMPLETED
Efficacy of Carbetocin in Prevention of Postpartum Hemorrhage in Obese Versus Non Obese Women
Lead Sponsor:
Cairo University
Conditions:
Obesity, Maternal
Post Partum Hemorrhage
Eligibility:
FEMALE
18-39 years
Phase:
PHASE1
PHASE2
Brief Summary
Postpartum hemorrhage \[PPH\] can have serious consequences and is the leading cause of maternal mortality globally. Uterine contractility plays an important role in post-delivery uterine involution; ...
Detailed Description
The American College of Obstetricians and Gynecologists (ACOG) updated their definition of postpartum hemorrhage (PPH) to be "blood loss greater than or equal to 1000 ml or blood loss accompanied by s...
Eligibility Criteria
Inclusion
- Healthy women with a singleton pregnancy undergoing a Cesarean delivery after at least 37 completed weeks of gestation under regional anesthesia.
- Aged (18-39) years and with signed informed consent.
Exclusion
- Emergency Cesarean Section due to fetal distress.
- Maternal comorbidities such as severe cardiovascular disorders, kidney or liver disorders, coagulopathies, as well as epilepsy.
- Uterine malformation.
- Fetal malformation.
- Known hypersensitivity to carbetocin or oxytocin.
- Uterine overdistention (as in polyhydramnios, twins, and fetal macrosomia)
- Injury of uterine vessels during CS.
Key Trial Info
Start Date :
July 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06217354
Start Date
July 6 2023
End Date
November 25 2023
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaimaa El Shemy
Giza, Cairo Governorate, Egypt, 11562